Milestone Pharmaceuticals, Inc. (MIST)

Milestone Pharmaceuticals' stock experienced a golden cross in November 2024. In November 2025, the company reported its third-quarter financial results and a PDUFA target date for CARDAMYST™. In December 2025, the stock reached a high before falling upon FDA approval news. TD Cowen upgraded the stock to a "buy" rating in December 2025. In January 2026, the European Medicines Agency accepted the Marketing Authorization Application for etripamil nasal spray, and HC Wainwright reiterated a "buy" rating. Zacks Research raised shares to a "strong-buy" rating in January 2026, and the U.S. availability of CARDAMYST™ was announced. In February 2026, the CEO was granted stock options and restricted stock units. As of February 5, 2026, the share price was $1.72, representing declines from the previous year and month.

Information directly detailing demand seasonality for Milestone Pharmaceuticals' products and services is not explicitly available. The price action of pharmaceutical stocks can be influenced by earnings announcements and new product launches. Specific seasonality in the demand for etripamil or other potential products is not publicly detailed.

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines in the United States and Canada, operating within the Healthcare sector, specifically in the Pharmaceuticals and Biotechnology industries. Their primary product candidate is etripamil (CARDAMYST™), a rapid-onset nasal spray designed for self-administration by patients to treat heart rhythm disturbances, which has completed Phase III clinical trials for PSVT and Phase II clinical trials for AFib-RVR.

Milestone Pharmaceuticals Inc. focuses its development and commercialization efforts on the United States and Canada. The company is headquartered in Montreal, Canada, and also has employees in Charlotte, North Carolina, United States.

Milestone Pharmaceuticals' brand reputation has been shaped by clinical progress and regulatory interactions, receiving an average recommendation of "Moderate Buy" from research firms. Zacks upgraded MIST to a "Strong Buy." The FDA's Complete Response Letter in April 2025 caused a stock drop, but analysts maintained "Buy" ratings. Retail investor sentiment remained bullish. Subsequent FDA approval in December 2025 and acceptance of the Marketing Authorization Application by the European Medicines Agency in January 2026 are positive for the company's reputation.

Milestone Pharmaceuticals Inc. has 74 institutional owners and shareholders holding a total of 35,612,849 shares, including major shareholders like Adage Capital Partners Gp, L.l.c., Propel Bio Management, LLC, and Orbimed Advisors Llc. The CEO, Joseph Oliveto, directly owns 0.48% of the company's shares.